Market research
DXB.AU Dimerix Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 117M
- P/E ratio
- Not available
- Analyst target
- 1.895
- Dividend yield
- Not available
- Beta
- 0.35
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000DXB7
- Market cap
- 117M
- P/E ratio
- Not available
- Analyst target
- 1.895
- Dividend yield
- Not available
- Beta
- 0.35
About
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Research context
Dimerix Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DXB.AU discussion.
5 years, 6 months ago
Dimerix Limited is currently in a long term downtrend where the price is trading 13.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Dimerix Limited's total revenue sank by 33.7% to $1K since the same quarter in the previous year.
Its net income has dropped by 31.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.4% to $-924K since the same quarter in the previous year.
Based on the above factors, Dimerix Limited gets an overall score of 2/5.